In another sign of the the growing prominence of generics at the US FDA, the Center for Drug Evaluation and Research's formal dispute resolution program is moving out of the Office of New Drugs.
Most of the appeals now reviewed involve generics, Center for Drug Evaluation and Research Director Janet Woodcock said in the announcement of the organizational change June 7
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?